Please fax all pages of completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Accredo® Specialty Pharmacy Prescription & Enrollment Form

Multiple Sclerosis-Self-administered Immunosuppressive



Four simple steps to submit your referral.

1 Patient Information	(0 -)	de copies of front and back of all medical tion insurance cards.			
New patient					
Patient's first name	Last name	Middle initial			
Preferred patient first name	Preferred patient	last name			
Sex at birth: Male Female Gender identity	Pronouns	Last 4 digits of SSN			
Date of birth Street address		Apt #			
City	State	Zip			
Home phone Cell phone	Email a	ddress			
Parent/guardian (if applicable)					
Home phone Cell phone					
Alternate caregiver/contact					
Home phone Cell phone .	Email a	ddress			
OK to leave message with alternate caregiver/contact					
, , , , ,	ner, please specify				
Deliver product to: Prescriber's office Patient's hor					
3 Clinical Information					
Primary ICD-10 code (REQUIRED):	Patient wt	Date wt obtained			
To expedite referral processing, please attach the following latent infection screenings (HIV, Hep B/C, TB, etc.), other	•	•			
Pregnancy test (+/-) Date					
		and email address above, you consent to receiving automated/artificial and health care. Standard data rates apply. Message frequency varies. Is must be completed to expedite prescription fulfillment. Idication needed			
Concurrent meds					

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

4 Prescribing Information

Medication	Strength/Formul	ation	Dire	ections	;							Q	uantity/Refi	lls
Aubagio® (teriflunomide)	7mg tablet 14mg tablet		Take one 7mg tablet by mouth once a day. Take one 14mg tablet by mouth once a day.						30-day supply 90-day supply Other					
										R	Refills			
Kesimpta® (ofatumumab)	20mg (0.4mL) prefilled pen		Loading dose: Inject contents of 1 pen subcutaneously at weeks 0, 1 and 2, then maintenance dose of 20mg once monthly beginning at week 4. Maintenance dose: Inject contents of 1 pen subcutaneously (0.4mL) once monthly.									4-week supply 12-week supply Refills		
Mavenclad [®] (cladribine)	10mg tablet		t	Treatment course: Year 1 Year 2 Take daily by mouth at intervals of 24 hours approximately the same time each day. Check the row corresponding to the patient's weight to prescribe the appropriate number of tablets. Tablets should be taken on consecutive days during each treatment week.								Refills: None		
	Weight Range (kg)		Number of 10mg tablets per week											
		-	Week 5									T		
		Day 1	Day 2	Day 3	Day 4	Day 5	Total Tablets Week 1	Day 1	Day 2	Day 3	Day 4	Day 5	Total Tablets Week 5	Total Tablet
	40 to <50	1	1	1	1	0	4	1	1	1	1	0	4	8 (80mg)
	50 to <60	1	1	1	1	1	5	1	1	1	1	1	5	10 (100m
	60 to <70	2	1	1	1	1	6	2	1	1	1	1	6	12 (120m
	70 to <80	2	2	1	1	1	7	2	2	1	1	1	7	14 (140m
	80 to <90	2	2	2	1	1	8	2	2	1	1	1	7	15 (150m
	90 to <100	2	2	2	2	1	9	2	2	2	1	1	8	17 (170m
	100 to <110 110 and above	2	2	2	2	2	10	2	2	2	2	2	9	19 (190m 20 (200m
	Other instructions:													
Other												R	30-day su 90-day su Other efills	pply
ncillary Supplies: (Pre vispense ancillary supp dminister the therapy	olies such as needles,	_	•		er, etc.	and ho	me medical e	equipme	nt nece	ssary to			end quantity s edication days	

If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)



Date Dispense as written Date Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

